Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoramidis in ATTR-CM (Open-Label Extension)
NCT04988386Phase 3Active, not recruiting
- Sponsor
- BridgeBio Pharma
- Start
- Oct 2021
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by BridgeBio Pharma. Primary endpoint: Treatment-Emergent Adverse Events at 60 months. Started Oct 2021; status: active, not recruiting.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT04988386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988386.